IHL-42X (Optimal Dose)

Drug identity checked against registry records

Also recorded as Phase 3 Investigational Product - IHL-42X

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101Incannex Healthcare LtdPhase 2, Phase 3Completed2025-05-20Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.